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Abstract 
Background: Accurate, non-invasive diagnosis of, and screening for, coronary artery disease 
(CAD) and restenosis after coronary revascularization has been a challenge due to either 
low sensitivity/specificity or relevant morbidity associated with current diagnostic modalities.   
Methods: To assess sensitivity and specificity of a new computerized, multiphase, resting 
electrocardiogram analysis device (MultiFunction-CardioGram
sm or MCG a.k.a. 3DMP) for 
the detection of relevant coronary stenosis (>70%), a meta-analysis of three published pro-
spective trials performed in the US on patient data collected using the US manufactured de-
vice and analyzed using the US-based software and New York data analysis center from pa-
tients in the US, Germany, and Asia was completed. A total of 1076 patients from the three 
trials (US - 136; Germany - 751; Asia - 189) (average age 62 ± 11.5, 65 for women, 60 for 
men) scheduled for coronary angiography, were included in the analysis. Patients enrolled in 
the trials may or may not have had prior angiography and/or coronary intervention. An-
giographic results in all studies were classified for hemodynamically relevant stenosis (> 70%) 
by two US based angiographers independently.   
Results: Hemodynamically relevant stenosis was diagnosed in 467 patients (43.4%). The de-
vice, after performing a frequency-domain, computational analysis of the resting ECG leads 
and computer-database comparison, calculated a coronary ischemia “severity” score from 0 
to 20 for each patient. The severity score was significantly higher for patients with relevant 
coronary stenosis (5.4 ± 1.8 vs. 1.7 ± 2.1). The study device (using a cut-off score for rele-
vant stenosis of 4.0) correctly classified 941 of the 1076 patients with or without relevant 
stenosis (sensitivity-91.2%; specificity-84.6%; NPV 0.942, PPV 0.777). Adjusted positive and 
negative predictive values (PPV and NPV) were 81.9% and 92.6%, respectively (ROC AUC = 
0.881 [95% CI: 0.860-0.903]). Subgroup analysis showed no significant influence of sex, age, 
race/nationality, previous revascularization procedures, resting ECG morphology, or par-
ticipating center on the device’s diagnostic performance.   
Conclusions: The new computerized, multiphase, resting ECG analysis device (MultiFunc-
tion-CardioGram
sm) has been shown in this meta-analysis to safely and accurately identify 




negative predictive value. Its potential use in the evaluation of symptomatic patients sus-
pected to suffer from coronary disease/ischemia is discussed. 
Key words: coronary artery disease, ECG analysis, Coronary Artery Stenosis 
Introduction 
Coronary artery disease (CAD) is the single 
leading cause of death in the developed world and is 
responsible for more than 30% of all deaths in most 
Organization for Economic Co-operation and Devel-
opment (OECD) countries [1]. Between 15% and 20% 
of all hospitalizations are the direct results of CAD [1]. 
CAD is responsible for 7.2 million deaths annually 
worldwide and is also an increasing cause of concern 
in the developing world [2]. In the USA alone the 
prevalence of CAD is estimated at 5.9% of all Cauca-
sians of age 18 and older [3].  
Accurate, non-invasive diagnosis of, and 
screening for, CAD and restenosis after coronary re-
vascularization has been an elusive challenge. Elec-
trocardiographic methods are routinely used as the 
first tools for initial screening and diagnosis in clinical 
practice. The low sensitivity and specificity of these 
methods makes them less than ideal diagnostic and 
prognostic indicators of CAD, however [4]. When 
used by non-specialists, the 12-lead resting ECG 
shows a sensitivity of less than 50% in diagnosing 
myocardial infarction [5]. 
Sensitivity, and to a lesser extent specificity, can 
be enhanced by different exercise or stress test meth-
ods, such as ECG stress testing, nuclear stress testing, 
or stress echocardiography. Nevertheless, even their 
sensitivity and specificity are limited, especially in 
single-vessel CAD [6]. Moreover, stress testing re-
quires significant personnel and time resources, is 
contraindicated in relevant patient populations, and 
bears a small but measurable morbidity and mortality 
[7, 8]. ECG-based methods are even less sensitive in 
patients after coronary revascularization [9,  10,  11] 
and may be contraindicated immediately after inter-
vention. Finally, in a recently published cohort study 
of 8176 consecutive patients presenting with chest 
pain [43], designed to determine whether the resting 
and exercise ECG provided prognostic information 
incremental to medical history, in accurately identi-
fying those at higher risk of Acute Coronary Syn-
drome and death during a median follow-up of 2.46 
years, showed that 47% of all events during follow-up 
occurred in patients with a negative exercise-ECG 
result. This study emphasized the limitations of rest-
ing or stress-ECGs for risk assessment and high-
lighted the need for new tests to assess this patient 
population. 
Coronary angiography remains the gold stan-
dard for the morphologic diagnosis of CAD and also 
allows revascularization during the same procedure 
[12, 13]. Coronary angiography is a relatively safe and 
effective intervention, yet it is resource-intensive, ex-
pensive, and invasive [14, 15]. Non-invasive cardiac 
imaging techniques such as multi-slice computed 
tomography (CT), high-resolution magnetic reso-
nance imaging/angiography (MRI/MRA), electron 
beam angiography (EBA), or positron-emission to-
mography with CT (PET-CT) have an alleged high 
sensitivity and specificity for detecting morphologic 
coronary lesions, and some even claim to permit the 
functional assessment of myocardial perfusion. Yet 
these techniques are also not ideal as they are, among 
other things, expensive, require significant staff and 
time resources, and lead to significant X-ray radiation 
exposure (CT, EBA, PET-CT) and/or contrast expo-
sure (MRI/MRA, CT, PET-CT) of the patient [16, 17].  
Several methods have been proposed and de-
veloped to enhance sensitivity and specificity of the 
resting ECG for diagnosis of symptomatic and as-
ymptomatic CAD. In theory, such methods may im-
prove diagnostic quality for non-specialists. Yet, di-
agnostic ECG computer programs have not been 
shown to be equal or superior to specialist physician’s 
judgment [18]. Moreover, studies comparing com-
puterized with manual ECG measurements in pa-
tients with acute coronary syndrome have shown that 
computerized measurements have diagnostic cut-offs 
that differ from manual measurements, and they may 
not be used interchangeably [19]. This is likely one of 
the reasons underlying the limited acceptance of such 
techniques in clinical practice.  
The present study compared a new com-
puter-enhanced, multi-phase, resting ECG analysis 
device, MultiFunction-CardioGramsm  or MCG  (a.k.a 
3DMP), to immediate and subsequent coronary an-
giography to evaluate the device’s accuracy in de-
tecting the presence and recurrence of hemodynami-
cally relevant CAD. 
Materials and Methods 
Data from three published trials of the use of 
MCG in the identification of relevant coronary steno-
sis was used in this meta-analysis. The included 




FDA-approved Premier Heart’sTM MCG device on 
patients undergoing standard coronary angiography 
at a total of seven medical centers (Westchester 
Medical Center, Valhalla, NY, Siegburg Heart Hospi-
tal, Siegburg, Germany, and five medical centers in 
Asia – Center A, Cardiovascular Center, Seoul Na-
tional University Bundang Hospital, Gyeonggi-do, 
South Korea, Center B, Mount Elizabeth Medical 
Centre, Singapore, Center C, Tokyo Heart Center, 
Tokyo, Japan, Center D, Wockhardt Heart Hospital, 
Mumbai, India, and Center E, HSC Medical Center, 
Kuala Lumpur, Malaysia) after its use was approved 
by the respective institutional review boards. Written 
informed consent was waived by each participant as a 
result of the disclosed non-risk designation of the 
study device. All patients received a full explanation 
and gave verbal consent to the study and the use of 
their de-identified data. Patients were only included if 
they underwent MCG testing prior to the scheduled 
reference coronary angiogram. 
Patients Enrolled 
A total of 1076 patients scheduled for coronary 
angiography were included in the meta-analysis. 
These represented a convenience sample of patients in 
the respective institutions in that each patient was 
already scheduled for the reference coronary an-
giography for any indication. Coronary angiographic 
data was recorded digitally and on cine angiographic 
film and was sent back to the United States for expert 
review by two independent US interventional cardi-
ologists. Thirty patients from HSC Medical Center, 
Kuala Lumpur, Malaysia had to be excluded from the 
study because angiograms were not made available 
for US external review due to unforeseen legal limita-
tions. Moreover, during the study a total of 84 patients 
(7.2%) were excluded due to inability to obtain ade-
quate MCG two-lead ECG tracing quality (64 West-
chester, 17 Siegburg, 3 Asia Centers) and were not 
included in this meta-analysis. The reasons for the 
poor technical quality of the MCG ECG recordings 
related primarily to unavoidable kinetic or electro-
magnetic field artifact, 60-cycle interference, lower 
frequency ambient noises, or poor lead placements. 
The included patient population had no overlap with 
any previously published or un-published study or 
with the actual independently validated MCG 
clinico-pathologic reference database of 40,000 pa-
tients accumulated over more than two decades. The 
MCG reference database used in the com-
puter-database comparative analysis of each patient’s 
data, was not modified or updated during the study 
period. Patient demographics, medical history, and 
risk factors apart from sex, age, height, weight and 
three samples of 82 second resting two ECG data were 
not recorded because they are not required for the 
MCG analysis. 
Study device 
The study device used in all patients in each in-
cluded trial, MCG (a.k.a. 3DMP), is manufactured in 
the US by Premier Heart, LLC, Port Washington, NY, 
and records a simultaneous 2-lead resting ECG from 
leads II and V5 for 82 seconds using proprietary 
hardware and software. The analog MCG ECG signal 
is amplified, digitized, and down-sampled to a sam-
pling rate of 100 Hz to reduce data transmission size; 
subsequent data transformations performed on the 
data do not require higher than 100 Hz/sec resolu-
tion. The digitized MCG ECG data was encrypted by 
the device at each study location and securely trans-
mitted over the Internet to a central server located in 
New York, NY for final analysis and reporting. 
At the central server location in New York, a se-
ries of Discrete Fourier Transformations (DFT) and 
post DFT signal averaging are performed on the data 
from the two ECG leads during the 82 second sam-
pling period followed by signal averaging. The final 
averaged digital data, obtained from multiple cardiac 
cycles, is then subjected to six mathematical trans-
formations (auto power spectrum, coherence, phase 
angle shift, impulse response, cross correlation, and 
transfer function – thus the trademark MultiFunction 
CardioGram) in addition to an amplitude histogram, 
which generates a large inventory of normalized 
mathematical indexes of abnormality. It is the pattern 
of these mathematical indexes of abnormality, ob-
tained from analysis of multiple cardiac cycles of the 
resting ECG not a specific time-based segment of data 
(i.e. ST segment), that contains the deviations from 
normal that are measured by the MCG device. The 
resulting mathematically integrated patterns of the 
abnormal indexes are then compared for their degree 
of abnormality to the abnormal index patterns in the 
reference database to reach a final diagnostic output. 
The diagnostic output is represented as a combination 
of the disease severity score from 0 to 20 and the 
presence of local or global ischemia, which indicates 
the level of coronary obstruction/myocardial ische-
mia that is present in the study patient. 
The reference clinico-pathologic database, 
against which the patient’s MCG index patterns are 
compared, originated from data-gathering trials 
conducted from 1978 to 2000 in more than 30 institu-
tions in Europe, Asia, and North America on indi-
viduals of varying ages and degrees of coronary dis-
ease state including 10,000 normals with no definable 




analyses included in the database were performed 
using the same “made in USA” equipment as in the 
included trials and were analyzed using the same 
software and hardware located at the central server 
location in New York. All MCG analyses in this da-
tabase have been validated against the final medical 
and angiographic diagnoses, confirmed by two inde-
pendent academic angiographers having access to all 
the diagnostic tests including angiography results, 
lab, and cardiac enzyme test results.  
One important difference between MCG and 
other ECG methods is that the MCG digitized analog 
electrocardiogram signals are locally recorded, but 
remotely analyzed at a central US data facility, due to 
the size and complexity of the digital signal process-
ing, the analysis by multiple mathematic functions, 
and the required comparison to the reference 
clinico-pathologic database. Further aspects of the 
underlying technology and methodology have been 
described elsewhere [20, 21, 22].  
MCG ECG acquisition and processing 
MCG tests were conducted as follows by a 
trained trial site technician as part of a routine elec-
trocardiographic workup received by each patient < 
24 hours (average 2.5 hrs) prior to angiography. Pa-
tients were tested while quietly lying supine follow-
ing 20 minutes of bed rest. Five ECG wires with elec-
trodes were attached from the MCG machine to the 
patient at the four standard limb lead and precordial 
lead V5 positions. An automatic 82-second simulta-
neous two-lead (leads V5 and II) ECG sample was 
acquired with amplification and digitization. During 
the sampling, the ECG tracings displayed on the MCG 
screen were closely monitored for tracing quality. 
The digital data was then de-identified, en-
crypted, and sent via a secure Internet connection to 
the central server in New York A second identical 
copy of the data was saved on the site MCG machine 
for post-study verification purposes before the data 
analysis was carried out. The quality of the tracing 
was visually rechecked and graded as “good,” “mar-
ginal,” or “poor”. A poor tracing was defined by one 
of the following: 
•  five or more 5.12-second segments of ECG data 
containing baseline artifact that deviated from the 
baseline by ≥2 mm and appears ≥10 times,  
•  two or more 5.12-second segments of ECG data 
containing baseline artifact that deviated from the 
baseline by ≥5 mm, 
•  in a 25-mm section of waveform in any 
5.12-second segment of the ECG data, the wave-
form strays from the baseline by ≥3 mm, 
•  a radical deviation away from the baseline angle 
of at least 80° with peak amplitude of ≥2 mm 
measured from the baseline, occurring two or 
more times, 
•  a single episode of radical deviation away from 
the baseline angle of at least 80° with peak am-
plitude of ≥5 mm measured from the baseline. 
A marginal tracing was defined by significant 
baseline fluctuations that did not meet the above cri-
teria. A good tracing had no significant baseline arti-
fact or baseline fluctuation. Tracings consistently 
graded as poor after repeated sampling were ex-
cluded from the present study, as noted above. All 
other tracings were included in the study. 
MCG provided automatic diagnosis of regional 
or global ischemia, including silent ischemia, due to 
coronary artery disease and calculated a severity score 
ranging from 0 to 20 where a higher score indicated a 
higher likelihood of myocardial ischemia due to 
coronary stenosis. Following the MCG manufacturer’s 
recommendation, a cut-off of 4.0 for the severity score 
was used in this meta-analysis; a score of 4.0 or higher 
was considered indicative of a hemodynamically 
relevant coronary artery stenosis of >70% in at least 
one large-sized vessel. 
Angiographers and staff at each study site were 
blinded to all MCG results and findings. The MCG 
technicians and all Premier Heart staff were blinded 
to all clinical data including pre-test probabilities for 
CAD and the coronary angiography findings from the 
study patients. 
Angiography 
After the MCG test, coronary angiography was 
performed at the discretion of the attending physi-
cians and following the standards of the institution. 
Angiographers were blinded to the MCG test results. 
Angiograms were classified by the respective angi-
ographer and independently by two US based aca-
demic research angiographers within 4 weeks after 
the angiogram. If the two independent investigators 
did not agree on the results, they discussed the an-
giograms and conferred with the US study monitor 
until agreement was reached. Angiograms were clas-
sified as follows: 
Non-obstructive CAD: angiographic evidence of 
coronary artery stenosis of ≤70% in a single or multi-
ple vessels. Evidence included demonstrable vaso-
spasm, delayed clearance of contrast medium indi-
cating potential macro- or micro-vascular disease, or 
CAD with at least 40% luminal encroachment ob-
servable on angiograms. These patients were classi-
fied as negative for hemodynamically relevant CAD 
(= “stenosis: no”). 




coronary artery sclerosis of >70% in a single or multi-
ple vessels, with the exception of the left main coro-
nary artery, where ≥50% was considered obstructive. 
These patients were classified as positive for hemo-
dynamically relevant CAD (= “stenosis: yes”). 
The results from the angiograms represent the 
diagnostic endpoint against which MCG was tested. 
Statistical Methods 
The data acquisition process, all angiography 
reports, and all MCG test results were monitored by 
an independent, US cardiologist, study monitor for-
merly based at the National Institutes of Health, who 
verified the double-blindness of the study and the 
data integrity. Two, independent, academic research 
cardiologists from US, reviewed the coronary an-
giographic data for each patient. In the event of dis-
agreement among the academic research cardiolo-
gists, discussion with the study monitor occurred un-
til agreement was achieved. 
Descriptive statistics were calculated for all 
variables. Differences between paired or two un-
paired mean values were analyzed with the t-test, and 
degrees of freedom were adjusted according to a 
variance estimate if the F-test could not show equality 
o f  v a r i a n c e s .  D i f f e r e n c e s  b e t w e e n  m o r e  t h a n  t w o  
mean values were analyzed with the Scheffé test 
where homogeneity of variances was assessed with 
the Levene statistic. For two-way and multi-way ta-
bles, Fisher’s exact test was used to calculate signifi-
cance levels. 
Odds ratios including 95% confidence intervals 
were calculated. Sensitivity and specificity were cal-
culated as were receiver operating characteristic 
(ROC) curves including an estimate of the area under 
the curve (AUC). Positive and negative predictive 
values (PPV, NPV) for the assessment of coronary 
stenosis were calculated with adjustment to preva-
lence of stenosis [23]. Moreover, to assess the per-
formance of the prediction of stenosis independent of 
the prevalence of stenosis, the positive and negative 
likelihood ratios (LR) were calculated [24]. A value of 
p <0.05 was considered statistically significant. All 
analyses were done with SPSS for Windows Version 
15 (SPSS Inc., Chicago, IL, USA). 
Results 
Final analysis was performed on 1076 patients. 
Patients excluded from analysis (as noted above in 
Methods) for either poor MCG digitized analog ECG 
signal quality or inability to undergo US expert re-
view of their angiography were not significantly dif-
ferent from the included patients with respect to age 
(59.4 +/- 10.7 vs. 61.3 +/- 12.9 years; p = 0.909) and sex 
(18% female vs. 30%; p = 0.210). Included patients 
comprised 686 men and 390 women with an average 
age of 62.0 +/- 11.5 years (21-88). Women were sig-
nificantly older than men (65.0 +/- 10.9 vs. 60.3 +/- 
11.4 years; p <0.05). (Table 1.) 
 
 
Table 1. Listing Of Average Age By Gender And By Center 
Of Patients Included In The Meta-Analysis. SD = standard 









Mean  65.32 60.46 62.24 
SD  10.58 10.73 10.92 
n  276 475 751 
Germany (Cen-
ter S) 
%  38.6 61.4 100.0 
Mean  65.14 59.58 61.26 
SD  10.80 13.43 12.92 
n 57  132  189 
Asia (Overall) 
%  32.1 67.9 100.0 
Mean  63.4 60.1 61.1 
SD 9.3 13.4  12.4 
n  19.0 46.0 65.0 
Asia - Center A 
%  30.3 69.7 100.0 
Mean  59.1 56.5 57.5 
SD 8.6 10.5  9.7 
n 7.0  12.0  19.0 
Asia - Center B 
%  37.9 62.1 100.0 
Mean  73.3 70.0 71.1 
SD 8.6 9.7 9.4 
n  15.0 29.0 44.0 
Asia - Center C 
%  35.2 64.8 100.0 
Mean  62.1 53.2 55.5 
SD  11.6 12.2 12.6 
n  16.0 45.0 61.0 
Asia - Center E 
%  29.4 70.6 100.0 
Mean  63.21 60.89 61.86 
SD  12.48 12.05 12.24 
n  57 79 136 
Center 
USA (Center W)
%  42.8 57.2 100.0 
Mean  64.98 60.34 62.02 
SD  10.90 11.44 11.46 
n  390 686 1,076 
Total 
%  38.0 62.0 100.0 
 
 
Gender distribution was not significantly dif-
ferent between all medical centers included in the 
meta-analysis (p = 0.340). Patients from Asia Center C, 
the Tokyo Heart Center, Tokyo, Japan, were signifi-
cantly older than those of all other Asia centers (p 
<0.05, details in table 1). Females were older in all 
centers, although differences did not always reach 
statistical significance. (Table 2.) 




Table 2. Average Age And Number Of Patients By Center, 
Sex, And Prior Revascularization Status. n = number of 
















Mean  64.34 59.94 68.36 61.71 62.24
SD 11.08  11.00  8.20 9.97 10.92
Germany 
(Siegburg) 
n 209  336  67 139  751 
Mean  64.60 57.73 68.00 64.91 61.26
SD  10.25 12.92 13.74 13.62 12.92
Asia 
(Multi-Center) 
n 48 98 9  34 189 
Mean  63.22 57.91 67.00 66.42 61.09
SD 9.53 13.73  11.10  10.61  12.38
Asia – Center 
A 
n 18.00  34.00  1.00  12.00  65.00
Mean  62.00 53.50 55.33 59.50 57.47
SD 6.73 6.16 10.69  13.56  9.69 
Asia – Center 
B 
n  4.00 6.00 3.00 6.00 19.00
Mean  71.17 69.19 82.00 70.92 71.11
SD 8.18 9.13 3.61 10.70  9.40 
Asia – Center 
C 
n 12.00  16.00  3.00  13.00  44.00
Mean  61.50 53.83 66.50 43.67 55.51
SD  11.80 11.77 13.44 16.80 12.59
Asia – Center 
E 
n 14.00  42.00  2.00  3.00  61.00
Mean 63.21  60.89  .N/A  .N/A  61.86




n  57  79        136 
Mean  64.18 59.66 68.32 62.34 62.02
SD 11.20  11.57  8.91  10.82  11.46
Total 
n 314  513  76  173  1,076
 
Two hundred forty nine patients (23% of those 
included in the analysis) had either percutaneous 
coronary intervention (PCI) (188 or 17.3%) or coronary 
artery bypass grafting (61 or 5.7%) for revasculariza-
tion 6 or more weeks before inclusion in the study. All 
other patients (827 or 77%) had no coronary revascu-
larization procedure in their medical history. Patients 
with previous revascularization were significantly 
older (p <0.05) and more frequently male, although 
this difference was not statistically significant (p = 
0.185). There were significant differences in the fre-
quency of patients with revascularization between the 
centers (details in table 2).  
Hemodynamically relevant coronary stenosis 
was diagnosed by angiography in 467 patients 
(43.4%). Although the percentage of patients with 
relevant coronary stenosis varied between centers, 
these differences were not significant (p = 0.563). 
There were no significant age differences between 
patients with and without angiographically proven 
relevant coronary stenosis (p = 0.389). There were also 
no significant gender differences (p = 1.000). Patients 
with revascularization procedures in their medical 
history were less frequently diagnosed with relevant 
coronary stenosis, although this difference was also 
not statistically significant (p = 0.117). However, pa-
tients with prior revascularization of any type were 
correctly identified as having relevant stenosis a 
higher percentage of the time (90% vs 87%) than pa-
tients without prior revascularization. In the case of 
prior PCI, patients with relevant stenosis were identi-
fied correctly by MCG 89% of the time and in the case 
of prior CABG, patients with relevant stenosis were 
identified correctly 93% of the time. The negative 
predictive value of an MCG score ≤ 4 in patients with 
prior PCI was 95.2% and in patients with prior CABG 
the NPV was 100 %. (Table 3). 
Table 3. Average Age By Center, Country, Sex, And Re-
vascularization Status And The Presence Or Absence Of 
Relevant Coronary Stenosis > 70%. n = number of patients 
in each group, SD = standard deviation. 
Coronary Stenosis >70% 
no yes 
 
Age (years) Age (years) 
Total
Mean 58.10  65.88  61.09 
SD 13.52  8.54  12.38 
A 
n 40  25  65 
Mean 57.22  57.70  57.47 
SD 9.22  10.58  9.69 
B 
n 9  10  19 
Mean 70.73  71.93  71.11 
SD 9.84  8.68  9.40 
C 
n 30  14  44 
Mean 55.36  55.68  55.51 
SD 13.85  11.18  12.59 
E 
n 33  28  61 
Mean 60.94  64.03  62.24 
SD 11.22  10.25  10.92 
S 
n 435  316  751 
Mean 57.66  65.38  61.86 
SD 12.15  11.24  12.24 
Centers 
W 
n 62  74  136 
Mean 60.94  64.03  62.24 
SD 11.22  10.25  10.92 
Germany 
n 435  316  751 
Mean 60.61  62.21  61.26 
SD 13.78  11.57  12.92 
Asia 
(Multi-Center)
n 112  77  189 
Mean 57.66  65.38  61.86 
SD 12.15  11.24  12.24 
Country
USA 
n 62  74  136 
Mean 59.08  64.00  61.38 
SD 11.93  10.71  11.63 
no 
n 441  386  827 
Mean 64.40  63.67  64.16 





n 168  81  249 
Mean 63.61  67.69  64.98 
SD 11.27  9.62  10.90 
female 
n 259  131  390 
Mean 58.28  62.49  60.34 
SD 11.77  10.69  11.44 
Sex 
male 
n 350  336  686 
Mean 60.55  63.94  62.02 
SD 11.85  10.65  11.46 
Total 
n 609  467  1,076 




The area under the receiver operator curve 
(ROC) for the entire study population was calculated 
to be 0.881 (0.86-0.903).(Figure 2). The coordinates of 
the curve confirmed that a cut-off score of 4.0 pro-
vides the best combination of sensitivity and specific-
ity for the prediction of relevant coronary stenosis 
from the MCG test that was reproducible throughout 
the participating centers.  
Patients without a significant coronary stenosis 
had a severity score ≤ 4.0 more frequently than those 
with a relevant coronary stenosis by a wide margin (p 
<0.001). The results indicate that MCG showed a sen-
sitivity of 91.2% and a specificity of 84.6% for the 
prediction of coronary stenosis. The Bayes Corrected 
positive predictive value (PPV) was 0.78, and the 
Bayes Corrected negative predictive value (NPV) was 
0.94. A positive likelihood ratio of over 6 and a nega-
tive likelihood ratio of 0.1 indicate a good to strong 
diagnostic value for this test (table 4).  
Sensitivity and specificity showed slight differ-
ences between participating centers, age, and gender 
groups, as well as between patients with and without 
revascularization procedures in their history. But for 
every group, sensitivity was always 90% or better and 
specificity better than 80% (detailed results in table 4), 
even for those in the revascularization group with a 
lower angiographic a priori pretest probability of 
0.325, or women having ages equal or greater than 65 
years old with the a priori pretest probability of only 
0.388. Since there were only a small number (n=43) of 
women under the age of 65 in this cohort, the devia-
tions may be considered as an epiphenomenon. From 
the most currently accumulated data (pending publi-
cation), the sensitivity and specificity for this group 
also falls between 90+% and 85+% respectively. The 
gender data in the trials for patients 65 years of age or 
older was also particularly noteworthy. For males and 
females 65 years old or older the sensitivity was 92% 
and 97% respectively, the specificity was 80% and 
79% respectively, and the negative predictive values 
were 88% and 98% respectively. These results dem-
onstrate a significant improvement in detection accu-
racy for hemodynamically relevant coronary stenosis 
in ≥ 65 year old females, a group that has heretofore 
been difficult to evaluate for obstructive coronary 
disease using existing ECG or stress imaging modali-
ties.(Table 4.) 
Table 4. Summary Of Overall MCG Data For The Detection Of Relevant Coronary Stenosis. n = number of 
cases; TP = true positives; TN = true negatives; FP = false positives; FN = false negatives; a priori = a priori probability of 
stenosis; Correct = fraction of correctly predicted cases; Sens = sensitivity; Spec = specificity; PPV = positive predictive 
value; NPV = negative predictive value; LR+ = positive likelihood ratio; LR- = negative likelihood ratio; OR = odds ratio; 
ROC AUC = receiver operating curve area under the curve for continuous severity score; 95% CI = 95% confidence 
interval; Lower = Lower boundary of 95% CI; Upper = Upper boundary of 95% CI; NaN = not a number; Revasc = coronary 
revascularization in medical history. 
                     ROC AUC        Odds Ratio 




















                                 
Total  1076 426 515 94 41  0.912 0.846 0.819 0.926 0.875  0.434 0.881 0.860 0.903  0.777  0.942  5.910 0.104 56.925  38.594 83.963 
USA  136 72 45 17  2  0.973  0.726  0.809  0.957 0.860  0.544 0.886 0.825 0.946 0.835  0.950  3.548  0.037  95.294 21.014 432.131
Asia  189 73 97 15  4  0.948  0.866  0.784  0.971 0.899  0.407 0.914 0.868 0.961 0.770  0.972  7.079  0.060  118.017 37.594 370.482
Germany  751  281 373 62 35  0.889 0.857 0.819 0.914 0.871  0.421 0.873 0.846 0.900  0.767  0.936  6.239 0.129 48.301  31.034 75.175 
female  390  121 221 38 10  0.924 0.853 0.761 0.957 0.877  0.336 0.885 0.849 0.920  0.617  0.978  6.296 0.089 70.371  33.878 146.172
male  686  305 294 56 31  0.908 0.840 0.845 0.905 0.873  0.490 0.881 0.853 0.908  0.839  0.908  5.673 0.110 51.653  32.377 82.405 
< 65 years  623  216 332 47 28  0.885 0.876 0.821 0.922 0.880  0.392 0.892 0.865 0.920  0.747  0.948  7.138 0.131 54.492  33.108 89.688 
65+ years  453  210 183 47 13  0.942 0.796 0.817 0.934 0.868  0.492 0.858 0.821 0.896  0.812  0.936  4.608 0.073 62.897  32.987 119.926
Female, < 
65 years 
184  43  121 12 8  0.843 0.910 0.782 0.938 0.891  0.277 0.896 0.838 0.953  0.579  0.975  9.345 0.172 54.198  20.754 141.533
Female, 
65+ years 
206  78  100 26 2  0.975 0.794 0.750 0.980 0.864  0.388 0.857 0.803 0.911  0.656  0.987  4.725 0.032 150.000 34.545 651.330
Male, < 65 
years 
439  173 211 35 20  0.896 0.858 0.832 0.913 0.875  0.440 0.886 0.853 0.920  0.795  0.931  6.300 0.121 52.147  29.051 93.605 
Male, 65+ 
years 
247  132 83  21 11  0.923 0.798 0.863 0.883 0.870  0.579 0.865 0.814 0.915  0.896  0.846  4.571 0.096 47.429  21.754 103.407
No Revasc  827  351 367 74 35  0.909 0.832 0.826 0.913 0.868  0.467 0.873 0.847 0.899  0.806  0.923  5.419 0.109 49.736  32.423 76.295 
PCI  188  47  120 15 6  0.887 0.889 0.758 0.952 0.888  0.282 0.894 0.841 0.947  0.552  0.981  7.981 0.127 62.667  22.938 171.205
CABG  61 28  28  5  0 1.000  0.848  0.848  1.000 0.918 0.459 0.902 0.814 0.989  0.826 1.000 6.600  0.000  NaN NaN  NaN   
Revasc of 
any type 
249  75  148 20 6  0.926 0.881 0.789 0.961 0.896  0.325 0.902 0.860 0.944  0.644  0.981  7.778 0.084 92.500  35.642 240.058
 





Figure 1 is a boxplot of MCG severity scores 
versus the documented presence or absence of rele-
vant coronary stenosis by coronary angiography. 
Note the clear separation of the mean and median 
scores in the two groups (p < .01). Figure 3 is a boxplot 
of MCG severity scores from all participating centers 
separated by whether or not the score was associated 
w i t h  t h e  f i n d i n g  o f  r e l e v a n t  c o r o n a r y  s t e n o s i s  o n  
coronary angiography. Again note the clear separa-
tion of the scores identifying patients with and with-
out coronary stenosis. Figure 4 shows the boxplot of 
MCG severity scores by sex and age groups and Fig-
ure 5 shows the boxplot of the MCG severity score 
data from patients with and without prior revascu-
larization. Please note that in all these boxplots and 
the sub-groups they depict, the MCG cut-off score of 
4.0 appears to clearly identify the populations within 





Figure 1. Severity Score Versus Coronary Stenosis In The Entire Study Population. Boxplots of MCG severity 
scores in all patients with and without relevant coronary stenosis. The boundaries of the box are Tukey’s hinges. The median 
is identified by the line inside the box. The length of the box is the interquartile range (IQR) computed from Tukey’s hinges. 
Values more than three IQR’s from the end of a box are labeled as extreme, denoted with an asterisk (*). Values more than 
1.5 IQR’s but less than 3 IQR’s from the end of the box are labeled as outliers (•). Whiskers show high/low values. Outliers 
and Extremes were included in the overall statistical analysis because the assumptions about the distribution of the data 









Figure 2. ROC For The Entire Study Population Using A Cut-Off MCG 
Score of 4.0. Area Under The Curve Was 0.881 (0.860 – 0.903). 





Figure 3. Severity Score Versus Coronary Stenosis In The Entire Study Population By Individual Center. 
Boxplots of MCG severity scores in patients with and without relevant coronary stenosis from the individual centers in-
cluded in the meta-analysis. The boundaries of the box are Tukey’s hinges. The median is identified by the line inside the box. 
The length of the box is the interquartile range (IQR) computed from Tukey’s hinges. Values more than three IQR’s from the 
end of a box are labeled as extreme, denoted with an asterisk (*). Values more than 1.5 IQR’s but less than 3 IQR’s from the 
end of the box are labeled as outliers (•). Whiskers show high/low values. Outliers and Extremes were included in the 
overall statistical analysis because the assumptions about the distribution of the data (normal distribution) were not violated.  
 
 
Figure 4. Severity Score Versus Coro-
nary Stenosis In The Entire Study 
Population By Sex And Age Groups. 
Boxplots of MCG severity scores in patients 
with and without relevant coronary stenosis 
according to sex and age groups. The 
boundaries of the box are Tukey’s hinges. The 
median is identified by the line inside the box. 
The length of the box is the interquartile 
range (IQR) computed from Tukey’s hinges. 
Values more than three IQR’s from the end of 
a box are labeled as extreme, denoted with an 
asterisk (*). Values more than 1.5 IQR’s but 
less than 3 IQR’s from the end of the box are 
labeled as outliers (•). Whiskers show 
high/low values. Outliers and Extremes were 
included in the overall statistical analysis be-
cause the assumptions about the distribution 
of the data (normal distribution) were not 
violated. 





Figure 5. Severity Score Versus Coronary Stenosis In The Entire Study Population According To Whether 
Patients Had Prior Revascularization Or Not. Boxplots of MCG severity scores in patients with and without relevant 
coronary stenosis according to whether the patients had prior revascularization. The boundaries of the box are Tukey’s 
hinges. The median is identified by the line inside the box. The length of the box is the interquartile range (IQR) computed 
from Tukey’s hinges. Values more than three IQR’s from the end of a box are labeled as extreme, denoted with an asterisk 
(*). Values more than 1.5 IQR’s but less than 3 IQR’s from the end of the box are labeled as outliers (•). Whiskers show 
high/low values. Outliers and Extremes were included in the overall statistical analysis because the assumptions about the 
distribution of the data (normal distribution) were not violated. 
 
Discussion 
The overall sensitivity of 91% and specificity of 
85% of the MCG device in this meta-analysis further 
confirms the strength of this device to identify rele-
vant coronary stenosis (>70%) in a population with a 
demonstrated pre-test risk of disease from 27.7% to 
43.4%. Subjects included in the trial were ambulatory 
patients who presented to their physicians for 
evaluation. Physicians used tools commonly at their 
disposal, including the available stress ECG modali-
ties, to decide whether to refer the patient for coro-
nary angiography, and had no knowledge the patient 
was a candidate for or would be included in an MCG 
study. The specific intent of the studies included in 
this meta-analysis was not to study MCG as a 
screening device, but instead to focus primarily on its 
potential as a diagnostic assay for relevant coronary 
stenosis.  
Resting ECG analysis, including 12-lead ECG, 
typically has significantly less sensitivity in detecting 
ischemia or obstructive coronary disease in patients 
with a low pre-test risk of disease. Clinical studies 
report a wide range for sensitivity from 20% to 70% 
for acute myocardial infarction (AMI) (review in [4]) 
and less for hemodynamically significant CAD 
ischemia [25]. Diagnostic yield from a resting ECG can 
be improved by exercise testing. Whereas exercise 
ECG has a reported specificity of over 80% under 
ideal conditions, in routine clinical use the sensitivity 
utilizing exercise-based ECG is typically not better 
than 50-60% [6, 26, 27, 28].  
Performance of exercise ECG testing can be fur-
ther enhanced by multivariate analysis of ECG and 
clinical variables. First studies into computerized, 
multivariate exercise ECG analysis showed good to 
excellent sensitivity in men and women (83% and 
70%, respectively) and specificity (93%, 89%) [29, 30]. 
These results were confirmed by a second group of 
researchers [31] and are similar to our findings with 
MCG. Other researchers used different statistical ap-
proaches and models of multivariate stress ECG 
analysis with different sets of variables included in 
the models [32, 33, 34, 35]. Although these approaches 
provided significantly better diagnostic performance 
than did standard exercise ECG testing, it appears 
that none of these methods has been implemented in 




should also be noted that none of the above refer-
enced studies included patients with previous coro-
nary revascularization. 
Stress echocardiography performed by experi-
enced investigators may provide better sensitivity and 
specificity than does stress ECG. Numerous studies 
into exercise echocardiography as a diagnostic tool for 
CAD have been done. Reported sensitivities range 
from 31% to over 90% and specificities from 46% to 
nearly 100% [36, 37, 38]. With experienced investiga-
tors, sensitivities of over 70% and specificities better 
than 85% can be expected. 
In a comprehensive systematic review of 16 pro-
spective studies, myocardial perfusion scintigraphy 
showed better positive and negative likelihood ratios 
than did routine exercise ECG testing [39]. However, 
wide variation between studies was reported with 
positive LR ranging from 0.95 to 8.77 and negative LR 
from 1.12 to 0.09. Another review of stress scintigra-
phy studies showed similar results, with a diagnostic 
accuracy of 85% but wide variation between studies 
(sensitivity 44%-89%, specificity 89%-94% for 2+ ves-
sel disease) [40]. In one study, the combination of 
stress ECG testing with myocardial scintigraphy us-
ing multivariate analysis provided only limited im-
provement of diagnostic accuracy [41].  
Whereas the reported diagnostic performance of 
stress echocardiography, myocardial scintigraphy, 
and stress scintigraphy are not dissimilar to what we 
found for MCG, imaging modalities can provide ad-
ditional information such as spatial localization that a 
resting ECG method cannot. 
MCG’s sensitivity and specificity for the detec-
tion of coronary stenosis was good to excellent in all 
patient groups included in this meta-analysis, with 
only moderate differences between groups. Moreover, 
there were only small differences in the results be-
tween the different centers. The optimal cut-off for the 
device-determined severity score was not different 
between patient groups or medical centers. These 
results indicate that MCG generates reproducible and 
stable results in diverse patient populations and dif-
ferent medical settings. Although the number of pa-
tients with a revascularization procedure in their 
medical history was small, the findings may further 
indicate that MCG provides reliable results in this 
patient group where other ECG or stress modalities 
often perform unsatisfactorily [9, 10, 11]. 
The endpoint of this study was the morphologic 
diagnosis of CAD on coronary angiography, whereas 
the investigated electro-physiologic method (MCG) 
assesses functional changes of electro-myocardial 
function secondary to changes in coronary blood flow, 
including both local and global forms of ischemia. 
Therefore, even under ideal conditions, a 100% coin-
cidence between angiographic findings and MCG 
results could not be expected. The disagreements 
mainly stem from under- or over-estimation of dis-
ease severity by MCG or the angiographer. Techni-
cians’ misidentifying poor quality tests as “accept-
able” for MCG interpretation is a source for potential 
discordance of MCG data and angiographic data. Fi-
nally, microvascular disease, not associated with de-
finable epicardial vessel lesions on angiography, re-
sulting in myocardial ischemia can create a false posi-
tive result, and critical stenosis of an epicardial vessel 
with a well-established collateral circulation resulting 
in a reduction of myocardial ischemia may result in a 
false negative result. Clinical correlation of MCG data 
will always be required by the treating physician. 
Resting and stress ECG analyses in CAD patients 
primarily focus on time-dependent ST-segment 
analysis and the detection of other abnormalities, such 
as Q-wave abnormalities, Q-T interval, etc. This is not 
comparable to the MCG concepts and technology, 
which performs a coronary disease/ischemia assess-
ment from a complex mathematical analysis per-
formed in both the frequency and the time domains.  
One limitation of the present study was that the 
angiographic results were not explicitly quantified 
using a suitable scoring system such as the BARI 
(bypass angioplasty revascularization investigation) 
system in all studies [42]. Still, the assessment of 
coronary lesions in the present study was consistent 
between two experienced US based angiographers 
who independently evaluated the angiograms. As the 
target criterion was hemodynamically relevant coro-
nary stenosis (>70%), implying an indication for 
therapeutic intervention, borderline lesions may have 
been classified as non-relevant. This may have further 
artificially reduced the calculated specificity of the 
MCG method. 
Another limitation may have been the recruit-
ment of patients. The patient population in all studies 
included in the meta-analysis represented a conven-
ience sample of patients from a larger group of con-
secutive patients scheduled for coronary angiography 
in the respective centers. Although this may limit the 
generalizability of the patient sample employed 
herein, the demographic distribution of this sample 
matches very well with the distributions reported in 
the literature for patients with CAD. In addition, 
~57% of all the participants, and in particular ~67% of 
revascularization group, ~72% of women under the 
age of 65, and ~61% of women ≥ 65 did not have 
hemodynamically significant CAD, with MCG sever-
ity scores ranging from completely normal (0.0-0.5) to 




that the study findings from the investigated patient 
group are valid for a general population of CAD pa-
tients. 
MCG performed very well in the group who had 
either prior PCI or prior CABG (Table 4). Despite the 
fact that in 188 patients with a prior PCI history there 
was a low a priori pre-test risk of coronary stenosis of 
28%, MCG correctly identified 89% of these patients 
as either having relevant stenosis or not. If the MCG 
score was below 4.0 in this group, the negative pre-
dictive value of the test was 95.2%. In the 61 patients 
with a history of prior CABG, the a priori pre-test risk 
of coronary stenosis was 46%. In this group, MCG 
correctly identified 92% as either having relevant 
stenosis or not, and if the score was below 4.0, the 
negative predictive value of the MCG test was 100%. 
These impressive findings suggest a role for MCG 
testing in the evaluation of disease progression or 
restenosis after revascularization. Further studies will 
need to be done pre- and post- revascularization to 
confirm this data. 
Finally, MCG was compared to angiography, but 
not directly to any other non-invasive diagnostic 
technology in the studies included in this 
meta-analysis. Therefore, inference about the poten-
tial superiority or inferiority of MCG compared to 
other ECG-based methods can only be drawn indi-
rectly from other studies. But even with this impor-
tant caveat, the data presented in this study on sensi-
tivity and specificity of MCG for the detection of 
relevant CAD is considerably better than the pub-
lished sensitivity, specificity, and negative predictive 
value of the most widely used stress ECG-based 
methods, including combined stress imaging tech-
niques. Additionally, the reported sensitivity, speci-
ficity, and negative predictive value of 97%, 79%, and 
98% respectively, for females 65 years of age or older 
is superior to published data for stress ECG and stress 
perfusion or wall motion imaging [6-8]. This presents 
a significant improvement in detection accuracy for 
hemodynamically relevant coronary stenosis in 
Medicare age females when the results are indirectly 
compared with other ECG or imaging stress diagnos-
tic modalities. In addition, the MCG analysis servers 
and methodology are available 24/7/365 to provide 
an objective, affordable, accurate, safe, and immedi-
ately accessible diagnosis on the Internet for patients 
in a wide variety of care settings including EMS, Ur-
gent Care Facilities, Emergency Rooms, and in- or 
out-patient clinics/hospitals. The use of the MCG in 
clinical practice has been reliably extended to monitor 
the progression or the development of ischemia and 
the improvement of ischemia after interventional 
and/or optimized medical therapies. Future research 
will also include direct comparisons between MCG 
and other commonly used or new non-invasive or 
invasive diagnostic and monitoring methods. 
In conclusion, the multi-functional mathematical 
systems analysis of the resting ECG in the frequency 
and time domains done using the MCG device ap-
pears to provide a high sensitivity and specificity for 
the identification of relevant CAD, as diagnosed by 
coronary angiography, in patients with a low or high 
pre-test risk of coronary disease, that appears to be 
equal to or better than those of any other resting or 
stress ECG/imaging methods currently used in clini-
cal practice. 
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